Second allogeneic hematopoietic SCT for relapsed ALL in children

被引：0

作者：

M Kato

Y Horikoshi

Y Okamoto

Y Takahashi

D Hasegawa

K Koh

J Takita

M Inoue

H Kigasawa

A Ogawa

Y Sasahara

K Kawa

H Yabe

H Sakamaki

R Suzuki

K Kato

机构：

[1] Saitama Children's Medical Center,Department of Hematology/Oncology

[2] Shizuoka Children's Hospital,Department of Hematology/Oncology

[3] Kagoshima University,Department of Pediatrics

[4] Nagoya University Graduate School of Medicine,Department of Pediatrics

[5] Hyogo Children's Hospital,Department of Hematology Oncology

[6] University of Tokyo,Department of Cell Therapy and Transplantation Medicine

[7] Osaka Medical Center and Research Institute for Maternal of Child Health,Department of Hematology/Oncology

[8] Kanagawa Children's Medical Center,Department of Hematology

[9] Niigata Cancer Center Hospital,Department of Pediatrics

[10] Tohoku University,Department of Pediatrics

[11] Tokai University,Department of Cell Transplantation and Regenerative Medicine

[12] Tokyo Metropolitan Cancer and Infectious Disease Center,Department of Hematology

[13] Komagome Hospital,Department Of HSCT Data Management And Biostatistics

[14] Nagoya University,undefined

[15] Division of Hematology/Oncology,undefined

[16] ,undefined

[17] Children's Medical Center,undefined

[18] Japanese Red Cross Nagoya First Hospital,undefined

来源：

Bone Marrow Transplantation | 2012年 / 47卷

关键词：

second transplantation; relapse; ALL; children;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

A second SCT is generally accepted as the only potentially curative approach for ALL patients that relapse after SCT, but the role of second SCT for pediatric ALL is not fully understood. We performed a retrospective analysis of 171 pediatric patients who received a second allo-SCT for relapsed ALL after allo-SCT. OS at 2 years was 29.4±3.7%, the cumulative incidence of relapse was 44.1±4.0% and non-relapse mortality was 18.8±3.5%. Relapse occurred faster after the second SCT than after the first SCT (117 days vs 164 days, P=0.04). Younger age (9 years or less), late relapse (180 days or more after first SCT), CR at the second SCT, and myeloablative conditioning were found to be related to longer survival. Neither acute GVHD nor the type of donor influenced the outcome of second SCT. Multivariate analysis showed that younger age and late relapse were associated with better outcomes. Our analysis suggests that second SCT for relapsed pediatric ALL is an appropriate treatment option for patients that have achieved CR, which is associated with late relapse after the first SCT.

引用

页码：1307 / 1311

页数：4

共 76 条

[1]

Arellano ML(2007)Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience Biol Blood Marrow Transplant 13 116-123

[2]

Langston A(2000)Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant Bone Marrow Transplant 25 41-45

[3]

Winton E(2001)Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation J Clin Oncol 19 3675-3684

[4]

Flowers CR(2004)Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant Bone Marrow Transplant 34 721-727

[5]

Waller EK(2010)Role of second hematopoietic stem cell transplantation in relapsed or refractory hematologic malignancies Transplant Proc 42 3225-3227

[6]

Blau IW(2009)Second allogeneic stem cell transplantation in myeloid malignancies Acta Haematol 122 185-192

[7]

Basara N(2009)Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT Leuk Res 33 840-842

[8]

Bischoff M(2000)Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM) Br J Haematol 108 400-407

[9]

Gunzelmann S(2002)Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON) Haematologica 87 331-332

[10]

Romer E(2001)Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant Br J Haematol 115 622-629

← 1 2 3 4 5 6 7 8 →